Table 2 Primary and secondary screening of antibodies against streptavidin and digoxigenin
Streptavidin | Digoxigenin STR > STR > AVI | Digoxigenin STR > AVI > STR | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Primary screening | Secondary Scr. | Primary screening | Secondary Scr. | Primary screening | Secondary Scr. | ||||||||||||
Library | Exp. | Screened | Hits | % | Screened | Hits | Screened | Hits | % | Screened | Hits | Screened | Hits | % | S/B >20 | Screened | Hits |
Hyperphage | I | 46 | 35 | 76% | 4 | 4 | 42 | 37 | 88% | 4 | 4 | 45 | 31 | 69% | 8 (26%) | 4 | 3 |
pEB30-Fab | II | 44 | 25 | 57% | 4 | 4 | 42 | 38 | 90% | 4 | 4 | 45 | 20 | 44% | 5 (25%) | 4 | 4 |
VCS-M13 | I | 47 | 41 | 87% | 4 | 4 | 42 | 37 | 88% | 4 | 4 | 45 | 37 | 82% | 9 (24%) | 4 | 4 |
pEB30-Fab | II | 35 | 33 | 94% | 4 | 4 | 42 | 40 | 95% | 4 | 4 | 45 | 39 | 87% | 22 (56%) | 4 | 4 |
Hyper/VCS | I | 46 | 38 | 83% | 4 | 4 | 42 | 41 | 98% | 4 | 4 | 45 | 36 | 80% | 7 (19%) | 4 | 4 |
pEB30-Fab | II | 47 | 38 | 81% | 4 | 4 | 42 | 38 | 90% | 4 | 4 | 45 | 37 | 82% | 7 (19%) | 4 | 4 |
VCS-M13 | I | 43 | 32 | 74% | 4 | 4 | 42 | 3 | 7% | 4 | 2 | 45 | 3 | 7% | 2 (67%) | 3 | 3 |
pEB32x-Fab | II | 43 | 35 | 81% | 4 | 3 | 42 | 8 | 19% | 3 | 3 | 45 | 5 | 11% | 0 (0%) | 4 | 4 |
VCS-M13 | I | 44 | 41 | 93% | 4 | 4 | 42 | 26 | 62% | 3 | 3 | 45 | 21 | 47% | 15 (71%) | 4 | 4 |
pEB32x-ScFv | II | 52 | 47 | 90% | 4 | 4 | 42 | 26 | 62% | 4 | 4 | 45 | 17 | 38% | 11 (65%) | 4 | 4 |
VCS-M13 | I | 47 | 1 | 2% | 1 | 1 | 42 | 0 | 0% | 0 | 0 | 45 | 0 | 0% | 0 (0%) | N.D. | N.D. |
pEB92-Fab | II | 43 | 17 | 40% | 4 | 4 | 42 | 3 | 7% | 3 | 1 | 45 | 0 | 0% | 0 (0%) | N.D. | N.D. |
STR > AVI > STR | IIIa | 45 | 0 | 0% | 0 (0%) | N.D. | N.D. | ||||||||||
STR > AVI > STR > AVI | IIIb | 45 | 4 | 9% | N.D. | 4 | 3 | ||||||||||